title: Emergence of antibiotic resistance in upper and lower respiratory tract infections.
abstract: The increase in antibiotic resistance is of great concern to the medical community. The treatment of respiratory tract infections are significantly impacted by resistance, as 67% of antibiotic use in adults and 87% in children is for the treatment of such infections. The most common pathogens implicated in these infections are Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis, and isolates of all 3 have developed resistance to some of the antibiotics currently on the market. In 1997, one third of S. pneumoniae strains were classified as penicillin resistant, up to 50% of H. influenzae strains produced beta-lactamase, and all M. catarrhalis strains produced beta-lactamase. As resistance can vary with geographic region and specific populations, one way to determine the-most effective antibiotic for an infection is to ascertain the resistance pattern of these pathogens from local laboratories or national surveillance studies. Breakpoints using pharmacodynamic data based on drug concentration present for at least 40% of the dosing interval, or area under the serum concentration curve:minimum inhibitory concentration ratios have been valuable for comparing the activities of oral agents. Of the currently available beta-lactams and macrolides, only amoxicillin/clavulanate and daily intramuscular ceftriaxone are active against more than 90% of all 3 respiratory pathogens. Newer quinolones are also active against these pathogens, but overuse is very likely to result in rapid development of resistance, and their use should be reserved for patients with treatment failure or significant drug allergies.
authors.forename: M R
authors.initials: MR
authors.lastname: Jacobs
mesh_terms: D000328:Adult; D002648:Child; D017714:Community-Acquired Infections; D004352:Drug Resistance, Microbial; D004363:Drug Utilization; D006193:Haemophilus influenzae / Q000472:pathogenicity; D006801:Humans; D001936:Moraxella catarrhalis / Q000472:pathogenicity; D017410:Practice Guidelines as Topic; D012141:Respiratory Tract Infections / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D013296:Streptococcus pneumoniae / Q000472:pathogenicity; D014481:United States / Q000453:epidemiology